Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background: In the AWARD-7 trial of participants with type 2 diabetes (T2DM) and moderate-to-severe CKD, dulaglutide (DU) treatment slowed decline in eGFR compared with insulin glargine (IG). Treatment with doses of either DU or IG resulted in similar levels of glycemic control and BP. The aim of this analysis was to determine the risk of clinical event outcomes between treatment groups. Methods: Participants with T2DM and CKD categories 3–4 were randomized (1:1:1) to 0.75 or 1.5 mg DU weekly or IG daily as basal therapy, with titrated insulin lispro, for 1 year. The time to occurrence of the composite outcome of ≥40% eGFR decline, ESKD, or death due to kidney disease was compared using a Cox proportional-hazards model. Results: Patients treated with 1.5 mg DU weekly versus IG daily for 1 year had a lower risk of ≥40% eGFR decline or ESKD events in the overall study population (5% versus 11%; hazard ratio, 0.45; 95% CI, 0.20 to 0.97; P =0.04). Most events occurred in the subset of patients with macroalbuminuria, where risk of the composite outcome was substantially lower for 1.5 mg DU versus IG (7% versus 22%; hazard ratio, 0.25; 95% CI, 0.10 to 0.68; P =0.006). No deaths due to kidney disease occurred. Conclusions: Treatment with 1.5 mg DU weekly was associated with a clinically relevant risk reduction of ≥40% eGFR decline or ESKD compared with IG daily, particularly in the macroalbuminuria subgroup of participants with T2DM and moderate-to-severe CKD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2i) independently reduce CV and kidney events.”
In the citing paper
“In a pre-specified exploratory analysis, the composite rate of ≥40% eGFR decline or kidney failure treated by dialysis or transplant was reduced by more than half, and in the macroalbuminuric group, the HR was 0.25 (95% CI, 0.10–0.68; P = 0.006) for these events over just 1 year of follow-up (Fig. 2) [55].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [55]
In the citing paper
“GLP-1RA-associated preservation of eGFR in participants with T2D and CKD has also been demonstrated in CVOTs and non-CVOTs [17,20,29].”
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Self-citationDiabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 3×
“42) 21/194 (11) Normoalbuminuria (UACR, <30 mg/g) eGFR-creatinine 2/34 (6) NA 0/44 NA 0/48 eGFR–cystatin C 3/34 (9) NA 0/44 NA 1/48 (2) Microalbuminuria (UACR, 30–300 mg/g) eGFR-creatinine 2/74 (3) 1.”
BackgroundLiraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965 · cited 1×
“Albuminuria is a major risk factor for CKD progression, particularly in those with macroalbuminuria (4).”
BackgroundTuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648 · cited 8×
“05, and two-sided 95% CIs are reported (10).”
BackgroundMethodInfluentialSelf-citationGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Self-citationLevey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.009 · Cited by 591
Cited by
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationHeerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306
Self-citationRossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad009 · Cited by 242
“GLP-1RA-associated preservation of eGFR in participants with T2D and CKD has also been demonstrated in CVOTs and non-CVOTs [17, 20, 29].”
BackgroundSelf-citationMann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03133-0 · Cited by 200
“Notably, GLP-1 RAs, including semaglutide, also provide substantial benefits for CV and CKD outcomes, death 1,2 and heart failure 5 .”
BackgroundSelf-citationMichos, E. D., Bakris, G. L., Rodbard, H. W., & Tuttle, K. R. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100502 · Cited by 125
Self-citationNauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Self-citationChen, J., Hsu, T., Liu, J.-H., Pan, H., Lai, C., Yang, S., & Wu, V. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.11.013 · Cited by 81
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 56
Cao, X., Wang, N., Yang, M. J., & Zhang, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146962 · Cited by 79
“A meta-analysis showed that TZD reduced microalbuminuria by an average of 25–30%, slowed the annual rate of decline in eGFR by about 1 mL/min/year, but increased hospitalization for heart failure [192].”
Baviera, M., Foresta, A., Colacioppo, P., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., Genovese, S., Caruso, I., & Giorgino, F. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01572-y · Cited by 52
“This was most evident among participants with macroalbuminuria, who had a 75% risk reduction, suggesting a potentially pronounced effect of dulaglutide to delay progression in participants with advanced CKD [34].”
BackgroundInfluentialDulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis
Botros, F. T., Gerstein, H. C., Malik, R., Nicolay, C., Hoover, A., Turfanda, I., Colhoun, H. M., & Shaw, J. E. (2023) · Diabetes Care · doi:10.2337/dc23-0231 · Cited by 42
Self-citationTransforming the Care of Patients with Diabetic Kidney Disease
Brosius, F. C., Cherney, D. Z. I., Gee, P. O., Harris, R. C., Kliger, A. S., Tuttle, K. R., & Quaggin, S. E. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.18641120 · Cited by 28
Self-citationRroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 34
“AWARD-7 Trial compared the effects of dulaglutide with insulin glargine in T2D patients with moderate to severe CKD. Dulaglutide led to a lower decline in eGFR and reduced UACR, particularly in patients with macroalbuminuria at baseline [115].”
BackgroundGlucagon‐like peptide‐1 receptor agonists and kidney outcomes
MacIsaac, R. J., Trevella, P., & Ekinci, E. I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13609 · Cited by 31
“37 At least two retrospective cohort studies have also suggested that GLP-1RAs can lower kidney function loss in comparison to insulin use.”
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
“8 years led to a 27% lower risk of incident MACE and a 32% lower risk of a composite renal outcome event compared to a placebo in patients with T2DM and either a history of cardiovascular disease or current kidney disease [93] (Figure 2).”
BackgroundPotential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Trevella, P., Ekinci, E. I., & MacIsaac, R. J. (2024) · Nephrology · doi:10.1111/nep.14336 · Cited by 26
“54”
Schechter, M., Cohen, C. M., Fishkin, A., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D. R., Chodick, G., Clark, A., Abrahamsen, T. J., Lawson, J., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01829-0 · Cited by 24
“However, the AWARD-7 study demonstrated that in patients with T2D and CKD, dulaglutide mitigated eGFR loss compared with insulin glargine [34], especially in a subgroup of patients with macroalbuminuria at baseline [35].”
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
“Also, dulaglutide reduced a relevant composite kidney outcome [i.e. ≥ 40% eGFR decline, end-stage renal disease (ESRD) or kidney death] in participants with severely increased albuminuria by 75% (7% versus 22%; 95% CI 0.10–0.68) [46 ].”
InfluentialIncretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Self-citationNatale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
Diker‐Cohen, T., Rudman, Y., Turjeman, ., Akirov, A., Steinmetz, T., Calvarysky, B., & Dotan, I. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101624 · Cited by 16
Innovative therapeutics for renoprotection: Where we are
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 16
“Importantly, reduction in the rate of eGFR decline was maintained in those with urinary albumin-to-creatinine ratio (UACR) > 300 mg/g (macroalbuminuria) at high-risk of kidney disease progression [67,84].”
BackgroundChu, L., Bradley, R., Auerbach, P., & Abitbol, A. (2024) · Diabetes, obesity and metabolism · doi:10.1111/dom.15834 · Cited by 11
Fishkin, A., Rozenberg, A., Schechter, M., Sehtman-Shachar, D. R., Aharon‐Hananel, G., Leibowitz, G., Yanuv, I., & Mosenzon, O. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70066 · Cited by 12
“In the AWARD‐7 trial, once‐weekly dulaglutide was not inferior to basal insulin in achieving glycaemic control and was associated with mitigation of eGFR loss in patients with T2D and CKD [48, 49].”
Santos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 11
“In the AWARD-7 trial, dulaglutide significantly slowed the decrease in eGFR compared to insulin glargine, especially for participants with baseline uACR > 300 mg/g[157,166].”
Beyond lipids: fenofibrate in diabetic retinopathy and nephropathy
Liu, M., Lim, S. T., Song, W., Coffman, T. M., & Wang, X. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.07.014 · Cited by 14
Garofalo, C., Borrelli, S., Liberti, M. E., Chiodini, P., Peccarino, L., Pennino, L., Polese, L., Gregorio, I. D., Scognamiglio, M., Ruotolo, C., et al. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.09.014 · Cited by 11
GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2030034 · Cited by 7
Self-citationLin, R., Hsu, C., Shih, M., Chien, K., & Wu, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70224 · Cited by 13
Păduraru, L., Zaha, D. C., Ghitea, T. C., Fodor, R., Vesa, C. M., & Popoviciu, M. S. (2025) · Medicina · doi:10.3390/medicina61112042 · Cited by 8
“Multidisciplinary care models, integrating physicians, nurses, dietitians, and social workers, have demonstrated improved outcomes in patients with diabetes and CKD by optimizing metabolic control, slowing renal decline, and enhancing quality of life [22].”
Halimi, J., Fauchier, L., Karras, A., Amouyal, C., Eladari, D., Rossignol, P., Choukroun, G. J., Zaoui, P., Girerd, N., & Hadjadj, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf426 · Cited by 9
Rico-Fontalvo, J. E., Daza-Arnedo, R., Elbert, A. E., Correa‐Rotter, R., Diná-Batlle, E., Lorca, E., de Moraes, T. P., Sánchez-Polo, V., & Builes-Montaño, C. E. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01854-8 · Cited by 6
“An exploratory analysis of AWARD‑7 [27] eval‑ uated outcomes by baseline albuminuria and in participants with macroalbuminuria, dulaglutide 1.5 mg reduced the risk of ≥ 40% eGFR decline or ESKD versus insulin glargine (HR 0.25, 95% CI 0.10–0.68; events 7% vs 22%), while the overall population…”
InfluentialDulaglutide Effect on Proteins Associated With CKD Progression
McFarlin, B. E., Tye, S. C., Satake, E., Dom, Z. I. M., Kechter, A., Wilson, J. M., Królewski, A. S., & Duffin, K. L. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.103789 · Cited by 3
RAAS blockade in the kidney life-cycle–treatment standard
Moriconi, D., García-Carro, C., Núñez, J. E., Correa‐Rotter, R., Tuttle, K., & Soler, M. J. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag090 · Cited by 1
Self-citationThe GLP-1 receptor agonist revolution comes to nephrology
Thomas, M. C., & Cooper, M. E. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00876-4 · Cited by 2
“…for 1 year was associated with a reduction in the risk of a ≥40% decline in eGFR or kidney failure in participants with T2DM and an eGFR of 60 ml/min/1.73 m 2 : the greatest protective benefit was seen in those with elevated urinary albumin excretion 6 , similar to the FLOW trial participants.”
InfluentialSchechter, M., Cohen, C. M., Fishkin, A., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D. R., Chodick, G., Clark, A., Abrahamsen, T. J., Lawson, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26592413
Baviera, M., Foresta, A., Colacioppo, P., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., Genovese, S., Caruso, I., & Giorgino, F. (2022) · Figshare · doi:10.6084/m9.figshare.20580413
Baviera, M., Foresta, A., Colacioppo, P., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., Genovese, S., Caruso, I., & Giorgino, F. (2022) · Figshare · doi:10.6084/m9.figshare.20580410
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“Among individuals with macroalbuminuria, dulaglutide reduced the risk of ≥ 40% eGFR decline or kidney failure by approximately 75% (hazard ratio 0.25) [110, 111].”
InfluentialYamanouchi, M., Sawa, N., Furuichi, K., & Wada, T. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101516
“35,36 In FLOW (eGFR 25-75 mL/min/1.73 m 2 ; urinary albumin-creatinine ratio 300-5,000), semaglutide reduced the primary kidney composite outcome (HR 0.76 [0.66-0.88]) and slowed the mean annual eGFR slope by 1.16 mL/min/1.73 m 2 per year versus placebo.”
Influential
Metadata
- Authors
- Tuttle, K. R., Rayner, B., Lakshmanan, M. C., Kwan, A. Y. M., Konig, M., Shurzinske, L., & Botros, F. T.
- Affiliations
- University of Washington (US)
- University of Cape Town (ZA)
- Eli Lilly (United States) (US)
- Lilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana
- Venue
- Kidney360
- Published
- 2021-02
- Volume
- 2
- Issue
- 2
- Pages
- 254-262
- ISSN
- 2641-7650 (ISSN-L)
- PMC
- PMC8740994
- OpenAlex
- W3112069718
- Cited by
- 42
- References
- 20
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 8 · 2023: 7 · 2022: 7 · 2021: 1
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Kidney360 (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lily and Company
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- dulaglutide, insulin glargine, type 2 diabetes, chronic kidney disease, macroalbuminuria, albuminuria, estimated glomerular filtration rate decline, end-stage renal disease, kidney disease mortality, GLP-1 receptor agonists, clinical outcomes
- MeSH terms
- Insulin Glargine, Albuminuria, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.